US91307C1027
US91307C1027
United Therapeutics Corporation
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 23.55B EUR | 23.12B EUR | 25B EUR | 21.27B EUR |
Enterprise Value | 20.19B EUR | 21.32B EUR | 23.72B EUR | 19.71B EUR |
Valuation Multiples | ||||
Trailing P/E | 19.67x | 17.64x | 19.42x | 21x |
Forward P/E | 18.06x | -- | -- | -- |
Price to Sales | 7.47x | 7.33x | 7.89x | 8.9x |
Price to Book | 3.66x | 3.61x | 4.24x | 3x |
EV/Revenue | 6.4x | 6.76x | 7.48x | 8.25x |
EV/EBITDA | 13.49x | 12.71x | 13.66x | 14.15x |
Price to FCF (P/FCF) | 42.28x | 21.26x | 24.72x | 32.77x |
EV/FCF | 36.24x | 19.6x | 23.45x | 30.37x |
FCF Yield | 2.37% | 4.7% | 4.05% | 3.05% |